Neurology Ultrasonic Aspirators Market – Introduction
Neurology ultrasonic aspirators are surgical devices which make use of low frequency ultrasonic vibrations for dissection of tissues and aspiration of the surgical field. A study published by the National Center for Biotechnology Information (NCBI) concluded that neurology ultrasonic aspirators are being used for the removal of brain tumors. For example, the Cavitron Ultrasonic Surgical Aspirator (CUSA) removes brain tumor without damaging healthy tissues and with high accuracy.
Versatility and user-friendliness are the key benefits of using neurology ultrasonic aspirators. Integrated neurology ultrasonic respirator is a high growth segment which is attributed to an ever-increasing incidence of brain tumor and neurological disease-related disabilities, as it is helpful to surgeons in combining the soft tissues for aspiration during a complicated cranial neurosurgery. This technology is used for surgery in orbital, lacrimal, neurological disease related, and skull base disabilities.
Standalone neurology ultrasonic aspirators allow users to independently control power and deliver precise fragmentation and irrigation with a single hand piece and suction.
Request a PDF of Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=72315
Global Neurology Ultrasonic Aspirators Market – Competitive Landscape
The global neurology ultrasonic aspirators market is consolidated, with presence of small number major players. Only a few players hold majority of the share as it is a niche market. Leading players in the global neurology ultrasonic aspirators market are Stryker Corporation, Cybersonics Inc., Meta Dynamic Inc., Xcellence Medical Technologies Pvt. Ltd., Springs GmbH, Olympus Corporation, Integra LifeSciences Corporation, and Söring GmbH.
Stryker Corporation
Incorporated in 2004 and headquartered in Michigan, USA, Stryker is a medical equipment and devices company. It offers products and services in orthopedics and neurosurgical devices. It has developed Sonopet iQ ultrasonic aspirator system which gives surgeons the capability to fragment, emulsify and aspirate soft tissue and bone during complex neurosurgical operations.
Meta Dynamic, Inc.
Founded in 2002 and headquartered in California, US, Meta Dynamic, Inc. is a firm that develops surgical navigation equipment for hospitals and surgical facilities in California. It has developed the Sonoca ultrasonic aspirator which facilitates tumor resection and tissue removal by using cavitation effect.
Global Neurology Ultrasonic Aspirators Market – Dynamics
The global neurology ultrasonic aspirators market is projected to be driven by rise in the number of deaths due to brain tumor and increase in number of traumatic brain injuries across the world. The market is also expected to witness technological advances such as wireless neurology ultrasonic aspirators. Lack of awareness restrains the global market; however, awareness campaigns about these devices are expected to increase adoption, especially in emerging economies.
- Rise in Number of Deaths due to Brain Tumor
The global neurology ultrasonic aspirators market is driven by rise in the number of deaths due to brain tumor. According to statistics provided by the National Brain Tumor Society, on average, 16,616 deaths due to brain tumor are reported across the globe each year. According to the American Society for Clinical Oncology, brain and other nervous system cancers are the 10th leading cause of death among men and women. Moreover, primary brain and CNS tumors are estimated to account for 17,760 deaths among adults (9,910 men and 7,850 women) in 2019.
- Increase in Incidence of Traumatic Brain Injuries
The global neurology ultrasonic aspirators market is driven by increase in incidence of traumatic brain injuries. According to the Centers for Disease Control and Prevention, the U.S. has had higher number of traumatic brain injuries (TBI) each year. Treatment of these injuries requires various instruments, including neurology ultrasonic aspirators. This boosts the growth of the market. According to the Centers for Disease Control and Prevention, in 2014, the U.S. witnessed about 2.87 million traumatic brain injury-related emergency department visits, hospitalizations, and deaths, including 837,000 injuries among children.
- Lack of Awareness about Availability of these Devices
Lack of awareness about the availability of these devices and corresponding treatments restrains the global neurology ultrasonic aspirators market. This results in people opting for alternative treatments which are better known.
Global Neurology Ultrasonic Aspirators Market – Segmentation
The global neurology ultrasonic aspirators market can be segmented based on product type, end-user, component type, and region.
In terms of product type, the global neurology ultrasonic aspirators market can be bifurcated into:
- Integrated
- Standalone
Based on end-user, the global neurology ultrasonic aspirators market can be classified into:
- Hospitals
- Ambulatory Surgical Centers
In terms of component type, the global ultrasonic aspirators market can be categorized into:
- Console/Generators
- Consumables/Hand Instruments
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Pre Book Full Report Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=72315<ype=S
Fact.MR has adopted multi-disciplinary approach to shed light on the evolution of the global Rare Neurological Disease Treatment market during the historical period of 2013 – 2017.
The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year of 2018, and key prospects over the forecast period 2018 – 2028.The global rare neurological disease treatment market is projected to expand at a stellar CAGR of over 8.5% and is anticipated to grow 2.3x between 2018 and 2028.
Extensive rounds of primary and a comprehensive secondary research have been leveraged by the analysts at Fact.MR to arrive at various estimations and projections of the Rare Neurological Disease Treatment market, both at global and regional levels.
The analysts have used numerous industry-wide prominent business intelligence tools to consolidate facts, figures, and market data into revenue estimations and projections in the Rare Neurological Disease Treatment market.After reading the Rare Neurological Disease Treatment market report, readers get insight into:Major drivers and restraining factors, opportunities and challenges, and the competitive landscapeNew, promising avenues in key regionsNew revenue streams for all players in emerging marketsFocus and changing role of various regulatory agencies in bolstering new opportunities in various regionsDemand and uptake patterns in key industries of the Rare Neurological Disease Treatment marketNew research and development projects in new technologies in key regional marketsChanging revenue share and size of key product segments during the forecast periodTechnologies and business models with disruptive potentialRequest for Sample Report with Statistical Info @ https://www.factmr.com/connectus/sample?flag=S_id=4594The Rare Neurological Disease Treatment market report offers assessment of prevailing opportunities in various regions and evaluates their shares of revenue by the end of different years of the assessment period.
Key regions covered comprise:North America (U.S., Canada)Latin America (Brazil, Mexico, Argentina, Rest of Latin America)Europe (Germany, Italy, France, U.K., Spain, Benelux, Russia, Rest of Europe)East Asia (China, Japan, South Korea)JapanAPEJ (China, India, Indonesia, Thailand, Singapore, Australia & New Zealand, Rest of Asia Pacific)South Asia & Oceania (India, Thailand, Indonesia, Malaysia, Australia & New Zealand, Rest of South Asia & Oceania)Middle East & Africa (GCC Countries, Turkey, Northern Africa, South Africa, Rest of Middle East & Africa)The evaluation of the competitive landscape in the Rare Neurological Disease Treatment market covers the profile of the following top players:Novartis AGPfizer, Inc.Johnson & Johnson Services, IncBayer AGGlaxoSmithKline PlcSanofi S.A.Allergan PlcMerck & Co., Inc.othersTo expand the understanding of opportunities in the global Rare Neurological Disease Treatment market report looks at close quarters into the opportunities and new avenues in following key segments:Hospitals PharmaciesRetail Pharmacies & Drug StoresOnline PharmaciesIn addition to understanding the demand patterns of various Distribution Channel, the report on the RARE NEUROLOGICAL DISEASE TREATMENT market also enumerates trends expected to attract investments by other various associated industries.On the basis of Drug Class types, the Rare Neurological Disease Treatment market report offers insight into major adoption trends for the following segments:Anti-depressantsAnti-psychoticsCholinesterase InhibitorsBiologicsOthers (Anti-vertigo, anti-seizure)By Route of Administration,InjectableOralBy Disease Indication,Alzheimer’s DiseaseNarcolepsyMultiple SclerosisAmyotrophic Lateral SclerosisOthersThe global Rare Neurological Disease Treatment market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period.
In coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.For More Detailed Information about Methodology @ https://www.factmr.com/connectus/sample?flag=RM_id=4594Some important questions that the Rare Neurological Disease Treatment market report tries to answer exhaustively are:Key strategic moves by various players in the Rare Neurological Disease Treatment market in recent years with respect to product launches, deals and tie-ups, and mergers and acquisitions, and divestment of shares.Which strategies will enable top players in the Rare Neurological Disease Treatment market to expand their geographic footprints?Which new business models are expected to change the course of growth of key regional markets in near future?Which technologies will witness most attractive research investments and what will be the key sources of funding for startups and new entrants?Which products segments have in recent years have seen new, lucrative application areas?What are COVID-19 implication on Rare Neurological Disease Treatment market and learn how businesses can respond, manage and mitigate the risks?Media Release: https://www.factmr.com/media-release/1367/global-rare-neurological-disease-treatment-market
Global RSV Diagnostics Market Research Report: By Product (Kits and Assays, Others), by Method (Rapid Antigen Detection Tests, Molecular Diagnostic Tests, Others), By End-User (Hospital and Clinics, Clinical Laboratory, Others) – Global Forecast Till 2023Market HighlightsRespiratory Syncytial Virus (RSV) is a virus that can cause serious respiratory infections such as pneumonia and bronchitis.
The increasing incidence rate of respiratory infections, growing demand for in-vitro diagnostics, and growing neonatal population are major factors propelling the growth of the market.
For instance, according to the Centres for Disease Control and Prevention, in the United States, RSV on an average lead to 57,527 hospitalizations among children below five years of age.
On the other hand, some factor such as lack of availability of specific treatment options for RSV infections and the high number of other pathogens that cause similar symptoms of respiratory illness may hamper the growth of the market during the assessment period.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/6217Regional AnalysisThe Americas is likely to dominate the global RSV diagnostics market during the forecast period.
For instance, as per the data stated by the Centres for Disease Control and Prevention, in the United States, RSV leads to an estimated 2.1 million outpatient visits among children below five years of age every year.
Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions.
The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.Report Scope:The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development.
Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.Request a Report Sample with Toc and figures to click here: http://marketgrowthanalysis.com/reports/sample/450Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships.
These cover all the WHO participating countries which are described in detail in the subsequent section.Report Includes:- An overview of the global markets for tropical disease treatments.- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.- A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies.- Representations of market shares by geography, company, and future outlook.- Insight on some of the newer drug candidates, clinical trials, and their end points.- Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika.- Profiles of major players in the industry.Request for enquiry on This Report at: http://marketgrowthanalysis.com/reports/enquiry/450Report SummaryNeglected tropical diseases are a significant cause of death and morbidity among affected communities around the world.
The global market for malaria treatments in 2015 was about $440.3 million (including preventive medicine for pregnant women and children under five years of age in Africa) and is expectedto reach $757.9 million by 2021.
Our projection of the market for Lymphatic Filariasis, for the year 2021, comes to $8,500.
This falls in line with WHO’s roadmap in which the global market for preventivechemotherapy will be reduced to near negligible with a very limited market for drugs.
